Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) had its price objective upped by analysts at HC Wainwright to $27.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's price objective points to a potential upside of 209.63% from the company's current price.
Other analysts also recently issued reports about the company. Wall Street Zen downgraded Rapt Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 21st. UBS Group lowered their price target on Rapt Therapeutics from $16.00 to $8.00 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Two analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, Rapt Therapeutics currently has an average rating of "Hold" and a consensus price target of $19.80.
Check Out Our Latest Analysis on RAPT
Rapt Therapeutics Trading Up 3.1%
Shares of RAPT opened at $8.72 on Thursday. The business's fifty day simple moving average is $7.89 and its two-hundred day simple moving average is $8.76. Rapt Therapeutics has a 12 month low of $5.67 and a 12 month high of $30.60. The company has a market cap of $144.23 million, a price-to-earnings ratio of -0.45 and a beta of -0.09.
Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($2.48) by $1.84. As a group, research analysts forecast that Rapt Therapeutics will post -2.14 EPS for the current year.
Hedge Funds Weigh In On Rapt Therapeutics
Large investors have recently made changes to their positions in the business. TCG Crossover Management LLC bought a new stake in shares of Rapt Therapeutics in the fourth quarter worth about $19,751,000. Orbimed Advisors LLC bought a new position in shares of Rapt Therapeutics during the fourth quarter valued at approximately $20,754,000. Foresite Capital Management VI LLC bought a new position in shares of Rapt Therapeutics during the fourth quarter valued at approximately $19,750,000. RTW Investments LP bought a new position in shares of Rapt Therapeutics during the fourth quarter valued at approximately $18,587,000. Finally, BVF Inc. IL bought a new position in shares of Rapt Therapeutics during the fourth quarter valued at approximately $14,595,000. 99.09% of the stock is currently owned by hedge funds and other institutional investors.
Rapt Therapeutics Company Profile
(
Get Free Report)
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Featured Stories
Before you consider Rapt Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapt Therapeutics wasn't on the list.
While Rapt Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
